We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.53B
AUM Growth
+$116M
Cap. Flow
-$73.8M
Cap. Flow %
-2.09%
Top 10 Hldgs %
47.92%
Holding
99
New
17
Increased
28
Reduced
21
Closed
18

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.1M
3
FOLD
Amicus Therapeutics
FOLD
+$40.3M
4
CNC icon
Centene
CNC
+$37.3M
5
STOK icon
Stoke Therapeutics
STOK
+$27.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$82.5M
2
ARRY
Array Biopharma Inc
ARRY
+$62.3M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$49.3M
4
PEN icon
Penumbra
PEN
+$47.5M
5
XNCR icon
Xencor
XNCR
+$46.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Miscellaneous 2.32%
3 Financials 2.17%
4 Energy 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ESTA icon
76
Establishment Labs
ESTA
$2.11B
$220K 0.01%
10,000
-132,167
-93% -$3.16M
NVRO
77
DELISTED
NEVRO CORP.
NVRO
$220K 0.01%
3,400
– –
VKTX icon
78
Viking Therapeutics
VKTX
$3.75B
$135K ﹤0.01%
16,260
– –
CSLT
79
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$33K ﹤0.01%
10,229
– –
ACRS icon
80
Aclaris Therapeutics
ACRS
$885M
– –
-11,320
Closed -$68K
ALGN icon
81
Align Technology
ALGN
$11.2B
– –
-143,200
Closed -$40.7M
ARVN icon
82
Arvinas
ARVN
$600M
– –
-150,955
Closed -$2.23M
ATRC icon
83
AtriCure
ATRC
$2.47B
– –
-325,000
Closed -$8.71M
AUPH icon
84
Aurinia Pharmaceuticals
AUPH
$2.17B
– –
-323,265
Closed -$2.1M
BIIB icon
85
Biogen
BIIB
$32.3B
– –
-165,300
Closed -$39.1M
CI icon
86
Cigna
CI
$73.7B
– –
-1,648
Closed -$265K
ICUI icon
87
ICU Medical
ICUI
$4.38B
– –
-51,721
Closed -$12.4M
IFRX icon
88
InflaRx
IFRX
$329M
– –
-2,182,638
Closed -$82.5M
PEN icon
89
Penumbra
PEN
$12.7B
– –
-323,170
Closed -$47.5M
SAGE
90
DELISTED
Sage Therapeutics
SAGE
– –
-1,450
Closed -$231K
SGRY icon
91
Surgery Partners
SGRY
$1.79B
– –
-15,900
Closed -$179K
SIBN icon
92
SI-BONE Inc
SIBN
$861M
– –
-538,730
Closed -$10.2M
TEVA icon
93
Teva Pharmaceuticals
TEVA
$42.5B
– –
-3,147,000
Closed -$49.3M
SWAV
94
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
– –
-300,000
Closed -$10M
PRAH
95
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-174,000
Closed -$19.2M
GWPH
96
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-2,820
Closed -$475K
HSKA
97
DELISTED
Heska Corp
HSKA
– –
-226,013
Closed -$19.2M
1 2 3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2019 Portfolio in Review

As of Q2 2019, Redmile Group held 99 positions worth $3.53B, up 3.4% from $3.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q2 2019 filing shows 17 new, 28 increased, 21 reduced and 18 closed positions. Its largest new stake was Sarepta Therapeutics: 412,000 shares worth $62.6M. The largest sale was InflaRx, an estimated $82.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2019 buy was Sarepta Therapeutics: 412,000 shares worth $62.6M.
  • Redmile Group added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $51.2M increase.
  • Redmile Group's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.3M.
  • Redmile Group fully exited InflaRx in Q2 2019, selling an estimated $82.5M.
  • Redmile Group's ten largest holdings make up 48% of its $3.53B portfolio in Q2 2019.
  • Redmile Group opened 17 new positions and closed 18 in Q2 2019.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $3.53B.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.